M1902 Efficacy and Safety of Entecavir and/or Tenofovir in Hepatitis B Cirrhotic Patients

Miquel, Mireia; Martínez, Óscar Núñez; Trapero-Marugán, María; Díaz-Sánchez, Antonio; Jiménez, Miguel Valle; Arenas, Juan; Palau, Antonio

doi:10.1016/s0016-5085(10)63836-x

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ETV or TDF are the preferred treatment options and both drugs have been shown to be effective but also generally safe in patients with decompensated disease. 1,[141][142][143][144][145] The licensed ETV dose for patients with HBV decompensated cirrhosis is 1 mg (instead of 0.5 mg for patients with compensated liver disease) once daily. Less potent NAs are not recommended as they have been demonstrated to have inferior outcomes as compared to potent ones.…”

Section: Recommendationsmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,000

3,081

View full text Add to dashboard Cite

Section: Recommendationsmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,000

3,081

View full text Add to dashboard Cite

“…A multinational, open-label, follow-up cohort study found that at least 5 year's TDF treatment in CHB patients resulted in 87% of patients showing histological improvement and 51% demonstrating regression of fibrosis (P < 0.0001) [39]. TDF with or without ETV also exhibited progressive improvement in the Model for End-Stage Liver Disease (MELD) scores in patients with decompensated cirrhosis in real-life clinical practice [40]. TDF also produced a similar treatment response and clinical outcome to ETV in patients with severe acute HBV exacerbation [41].…”

Section: Anti-hbv Treatment With Nas In Patients Listed For Ltmentioning

confidence: 99%

Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma

Zhang

2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Introduction: Hepatocellular carcinoma (HCC) is a leading cause of death globally and is frequently seen following Hepatitis B virus (HBV) or Hepatitis C virus infection. Areas with high HBV infection rates, such as Asia and sub-Saharan Africa, are therefore also high-risk areas for HCC. Areas covered: This review identifies and discusses the current evidence from robust clinical trials which have investigated the benefits of Nucleos(t)ide analogue (NA) antiviral therapy in HBV-related HCC patients, including HCC patients that underwent liver transplantation and HCC patients with or without curative treatment. In addition, we assess how this evidence has influenced current clinical practice, with a particular focus on those areas of high HBV infection rates. Expert commentary: A number of studies have assessed whether NA antiviral treatment can improve the prognosis of HBV-related HCC patients. In this review we evaluate the current evidence, including that from trials in Asia, for antiviral NA treatments in HBV-related HCC patients. We also focus on those NAs with a high genetic barrier to resistance (i.e. ETV or TDF), on different therapeutic approaches, and on the future evidence that is required in this field. ARTICLE HISTORY

show abstract

“…The research conducted by Heinrichs et al (2011) revealed an important role for MIF in pathological liver damage; similarly, the results of our preliminary study (Yu et al, 2012) indicated the participation of MIF in the overall occurrence and development of viral hepatitis type B, liver cirrhosis, liver cancer, and other hepatopathies and that changes in the MIF levels were closely related to the extent of liver tissue damage. Miquel et al (2013) reported that immune tolerance was broken following antiviral therapy with Baraclude ® such that the level of MIF in the liver tissue was initially enhanced and then gradually reduced. Ismail et al (2013) reported that hepatic cells secreted less MIF following the antiviral therapy with Baraclude ® , thus reducing the secretion of vascular endothelial growth factor, transforming growth factor, ILs, matrix metalloproteinases, and various other cytokines, relieving inflammation, and consequently reducing the malignant transformation of hepatic cells.…”

Section: Baracludementioning

confidence: 99%

Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude® treatment

Yu¹,

Zhang²,

Li³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study aimed to determine the relationship between changes in the serum levels of macrophage migratory inhibitory factor (MIF), interleukin (IL) 17, and IL-10 during chronic hepatitis B treatment via Baraclude ® (Bristol-Meyers Squibb). Thirty-six patients with chronic hepatitis B and 24 healthy individuals were selected as the experimental and control groups, respectively, and the serum levels of MIF, IL-17, and IL-10 were measured during the period in which the experimental group was treated with oral Baraclude ® ; meanwhile, the alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and HBV marker (M) levels were measured in the experimental group. In the experimental group, the ALT and HBV-DNA levels began to exhibit obvious decreases in week 4, and the MIF and IL-17 levels exhibited obvious increases in week 4 followed by gradual decreases; however, the IL-10 level exhibited an obvious decrease in week 12 and then (2015) increased gradually. These changes were significant when compared with the control group (P < 0.05). In conclusion, Baraclude ® treatment not only actively suppressed HBV but also indirectly balanced the MIF, IL-17, and IL-10 levels and reduced the liver inflammatory response.

show abstract

M1902 Efficacy and Safety of Entecavir and/or Tenofovir in Hepatitis B Cirrhotic Patients

Cited by 3 publications

References 0 publications

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma

Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude® treatment

Contact Info

Product

Resources

About